{"id":529044,"date":"2024-06-12T08:58:06","date_gmt":"2024-06-12T06:58:06","guid":{"rendered":"https:\/\/www.interactiegroep.nl\/?page_id=529044"},"modified":"2024-11-04T14:53:15","modified_gmt":"2024-11-04T13:53:15","slug":"infliximab","status":"publish","type":"page","link":"https:\/\/www.interactiegroep.nl\/en\/infliximab\/","title":{"rendered":"Should I switch or should I stay?"},"content":{"rendered":"<p><img decoding=\"async\" data-src=\"\/wp-content\/uploads\/2024\/06\/header2-infliximab.jpg\" alt=\"\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\" style=\"--smush-placeholder-width: 1646px; --smush-placeholder-aspect-ratio: 1646\/472;\" data-srcset=\"https:\/\/www.interactiegroep.nl\/wp-content\/uploads\/2024\/06\/header2-infliximab.jpg 1646w, https:\/\/www.interactiegroep.nl\/wp-content\/uploads\/2024\/06\/header2-infliximab-300x86.jpg 300w, https:\/\/www.interactiegroep.nl\/wp-content\/uploads\/2024\/06\/header2-infliximab-1024x294.jpg 1024w, https:\/\/www.interactiegroep.nl\/wp-content\/uploads\/2024\/06\/header2-infliximab-768x220.jpg 768w, https:\/\/www.interactiegroep.nl\/wp-content\/uploads\/2024\/06\/header2-infliximab-1536x440.jpg 1536w, https:\/\/www.interactiegroep.nl\/wp-content\/uploads\/2024\/06\/header2-infliximab-18x5.jpg 18w, https:\/\/www.interactiegroep.nl\/wp-content\/uploads\/2024\/06\/header2-infliximab-600x172.jpg 600w, https:\/\/www.interactiegroep.nl\/wp-content\/uploads\/2024\/06\/header2-infliximab-350x100.jpg 350w\" data-sizes=\"auto\" data-original-sizes=\"(max-width: 1646px) 100vw, 1646px\"><br \/>\n<iframe data-src=\"https:\/\/player.vimeo.com\/video\/1026118344\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\" data-load-mode=\"1\"><\/iframe><\/p>\n<h2>Wetenschappelijk programma<\/h2>\n<table>\n<tbody>\n<tr>\n<td>20:30-20:35<\/td>\n<td>Welkom<\/td>\n<td>\n<p>Ad van Bodegraven<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>20:35-20:55<\/td>\n<td>Laatste stand van zaken van TDM bij infliximab SC<\/td>\n<td>\n<p>Luc Derijks<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>20:55-21:15<\/td>\n<td>Waarom staan niet alle infliximab patienten op infliximab SC?<\/td>\n<td>\n<p>Ad van Bodegraven<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>21:15-21:30<\/td>\n<td>Discussie en afsluiting<\/td>\n<td>\n<p>Beide<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<div>\n<ul>\n<li>IBD: Inflammatory Bowel Disease<\/li>\n<li>SC: Subcutaan<\/li>\n<li>TDM: Therapeutic Drug Monitoring<\/li>\n<\/ul>\n<\/div>\n<h2>Accreditatie<\/h2>\n<table>\n<tbody>\n<tr>\n<td>Nederlandse Vereniging van Maag-Darm-Leverartsen<\/td>\n<td>Met 1 punt geaccrediteerd<\/td>\n<\/tr>\n<tr>\n<td>Verpleegkundig Specialisten Register &#8211; V&#038;VN<\/td>\n<td>Met 1 punt geaccrediteerd<\/td>\n<\/tr>\n<tr>\n<td>Nederlandse Vereniging van Ziekenhuisapothekers (NVZA)<\/td>\n<td>Met 1 punt geaccrediteerd<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><img decoding=\"async\" data-src=\"\/wp-content\/uploads\/2024\/06\/sprekers-infliximab.jpg\" alt=\"\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\" style=\"--smush-placeholder-width: 1621px; --smush-placeholder-aspect-ratio: 1621\/857;\" data-srcset=\"https:\/\/www.interactiegroep.nl\/wp-content\/uploads\/2024\/06\/sprekers-infliximab.jpg 1621w, https:\/\/www.interactiegroep.nl\/wp-content\/uploads\/2024\/06\/sprekers-infliximab-300x159.jpg 300w, https:\/\/www.interactiegroep.nl\/wp-content\/uploads\/2024\/06\/sprekers-infliximab-1024x541.jpg 1024w, https:\/\/www.interactiegroep.nl\/wp-content\/uploads\/2024\/06\/sprekers-infliximab-768x406.jpg 768w, https:\/\/www.interactiegroep.nl\/wp-content\/uploads\/2024\/06\/sprekers-infliximab-1536x812.jpg 1536w, https:\/\/www.interactiegroep.nl\/wp-content\/uploads\/2024\/06\/sprekers-infliximab-18x10.jpg 18w, https:\/\/www.interactiegroep.nl\/wp-content\/uploads\/2024\/06\/sprekers-infliximab-600x317.jpg 600w\" data-sizes=\"auto\" data-original-sizes=\"(max-width: 1621px) 100vw, 1621px\"><\/p>\n<div>\n<p>Deze uitzending wordt mede mogelijk gemaakt door: Celltrion Healthcare NL<\/p>\n<p>NL-REMSC-24-00012 &#8211; Juni 2024<\/p>\n<\/div>\n<p><!--more--><br \/>\n<!-- {\"type\":\"layout\",\"children\":[{\"type\":\"section\",\"props\":{\"image_position\":\"center-center\",\"style\":\"default\",\"title_breakpoint\":\"xl\",\"title_position\":\"top-left\",\"title_rotation\":\"left\",\"vertical_align\":\"\",\"width\":\"default\"},\"children\":[{\"type\":\"row\",\"props\":{\"width\":\"small\"},\"children\":[{\"type\":\"column\",\"props\":{\"image_position\":\"center-center\",\"position_sticky_breakpoint\":\"m\"},\"children\":[{\"type\":\"image\",\"props\":{\"image\":\"wp-content\\\/uploads\\\/2024\\\/06\\\/header2-infliximab.jpg\",\"image_border\":\"rounded\",\"image_svg_color\":\"emphasis\",\"margin\":\"medium\"}},{\"type\":\"video\",\"props\":{\"margin\":\"default\",\"video\":\"https:\\\/\\\/player.vimeo.com\\\/video\\\/1026118344\",\"video_controls\":true,\"video_height\":\"1080\",\"video_width\":\"1920\"}},{\"type\":\"headline\",\"props\":{\"content\":\"Wetenschappelijk programma\",\"title_decoration\":\"divider\",\"title_element\":\"h2\",\"title_style\":\"h3\"}},{\"type\":\"table\",\"props\":{\"image_svg_color\":\"emphasis\",\"link_style\":\"default\",\"link_text\":\"Read more\",\"meta_style\":\"\",\"show_content\":true,\"show_image\":true,\"show_link\":true,\"show_meta\":true,\"show_title\":true,\"table_hover\":false,\"table_justify\":false,\"table_order\":\"2\",\"table_responsive\":\"overflow\",\"table_style\":\"striped\",\"table_width_meta\":\"shrink\",\"table_width_title\":\"shrink\"},\"children\":[{\"type\":\"table_item\",\"props\":{\"content\":\"\n\n<p>Ad van Bodegraven<\\\/p>\",\"meta\":\"Welkom\",\"title\":\"20:30-20:35\"}},{\"type\":\"table_item\",\"props\":{\"content\":\"\n\n<p>Luc Derijks<\\\/p>\",\"meta\":\"Laatste stand van zaken van TDM bij infliximab SC\",\"title\":\"20:35-20:55\"}},{\"type\":\"table_item\",\"props\":{\"content\":\"\n\n<p>Ad van Bodegraven<\\\/p>\",\"meta\":\"Waarom staan niet alle infliximab patienten op infliximab SC?\",\"title\":\"20:55-21:15\"}},{\"type\":\"table_item\",\"props\":{\"content\":\"\n\n<p>Beide<\\\/p>\",\"meta\":\"Discussie en afsluiting\",\"title\":\"21:15-21:30\"}}]},{\"type\":\"text\",\"props\":{\"column_breakpoint\":\"m\",\"content\":\"\n\n<ul>\\n\n\n<li>IBD: Inflammatory Bowel Disease<\\\/li>\\n\n\n<li>SC: Subcutaan<\\\/li>\\n\n\n<li>TDM: Therapeutic Drug Monitoring<\\\/li>\\n<\\\/ul>\",\"margin\":\"default\"}},{\"type\":\"headline\",\"props\":{\"content\":\"Accreditatie\",\"title_decoration\":\"divider\",\"title_element\":\"h2\",\"title_style\":\"h3\"}},{\"type\":\"table\",\"props\":{\"image_svg_color\":\"emphasis\",\"link_style\":\"default\",\"link_text\":\"Read more\",\"meta_style\":\"\",\"show_content\":true,\"show_image\":true,\"show_link\":true,\"show_meta\":true,\"show_title\":true,\"table_hover\":false,\"table_justify\":false,\"table_order\":\"2\",\"table_responsive\":\"overflow\",\"table_style\":\"striped\",\"table_width_meta\":\"shrink\",\"table_width_title\":\"shrink\"},\"children\":[{\"type\":\"table_item\",\"props\":{\"meta\":\"Met 1 punt geaccrediteerd\",\"title\":\"Nederlandse Vereniging van Maag-Darm-Leverartsen\"}},{\"type\":\"table_item\",\"props\":{\"meta\":\"Met 1 punt geaccrediteerd\",\"title\":\"Verpleegkundig Specialisten Register - V&VN\"}},{\"type\":\"table_item\",\"props\":{\"meta\":\"Met 1 punt geaccrediteerd\",\"title\":\"Nederlandse Vereniging van Ziekenhuisapothekers (NVZA)\"}}]},{\"type\":\"image\",\"props\":{\"image\":\"wp-content\\\/uploads\\\/2024\\\/06\\\/sprekers-infliximab.jpg\",\"image_border\":\"rounded\",\"image_svg_color\":\"emphasis\",\"margin\":\"medium\"}},{\"type\":\"text\",\"props\":{\"column_breakpoint\":\"m\",\"content\":\"\n\n<p>Deze uitzending wordt mede mogelijk gemaakt door: Celltrion Healthcare NL<\\\/p>\\n\n\n<p>NL-REMSC-24-00012 - Juni 2024<\\\/p>\",\"margin\":\"default\"}}]}]}]}],\"version\":\"4.4.9\"} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Wetenschappelijk programma 20:30-20:35 Welkom Ad van Bodegraven 20:35-20:55 Laatste stand van zaken van TDM bij infliximab SC Luc Derijks 20:55-21:15 Waarom staan niet alle infliximab patienten op infliximab SC? Ad van Bodegraven 21:15-21:30 Discussie en afsluiting Beide IBD: Inflammatory Bowel Disease SC: Subcutaan TDM: Therapeutic Drug Monitoring Accreditatie Nederlandse Vereniging van Maag-Darm-Leverartsen Met 1 punt [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-529044","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.interactiegroep.nl\/en\/wp-json\/wp\/v2\/pages\/529044","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.interactiegroep.nl\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.interactiegroep.nl\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.interactiegroep.nl\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.interactiegroep.nl\/en\/wp-json\/wp\/v2\/comments?post=529044"}],"version-history":[{"count":0,"href":"https:\/\/www.interactiegroep.nl\/en\/wp-json\/wp\/v2\/pages\/529044\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.interactiegroep.nl\/en\/wp-json\/wp\/v2\/media?parent=529044"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}